Top-News

Pharmaxis ADR News

Keine aktuellen Kursdaten verfügbar
WKN: A0F6C9
ISIN: US71715J1051
US-Symbol: PXSLY
Typ: Aktie

Pharmaxis ADR News

15.11.18 - PR Newswire
Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound
Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound PR Newswire
15.11.18 - PR Newswire
Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound
Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound PR Newswire
11.10.18 - PR Newswire
Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound
Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound PR Newswire
11.10.18 - PR Newswire
Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound
Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound PR Newswire
24.08.17 - PR Newswire
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH PR Newswire
24.08.17 - PR Newswire
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH PR Newswire
10.03.17 - PR Newswire
Synairgen plc: Additional Positive Data in Lung Fibrosis
Synairgen plc: Additional Positive Data in Lung Fibrosis PR Newswire
10.03.17 - PR Newswire
Synairgen plc: Additional Positive Data in Lung Fibrosis
Synairgen plc: Additional Positive Data in Lung Fibrosis PR Newswire
21.09.15 - PR Newswire
Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A
Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A PR Newswire
21.09.15 - PR Newswire
Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A
Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A PR Newswire
05.08.15 - PR Newswire
Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis PR Newswire
05.08.15 - PR Newswire
Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis PR Newswire
17.05.15 - PR Newswire
Boehringer Ingelheim Acquires Pharmaxis' Phase 1 Anti-inflammatory Drug Candidate
Boehringer Ingelheim Acquires Pharmaxis' Phase 1 Anti-​inflammatory Drug Candidate PR Newswire

Newssuche

Videos

18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »